<DOC>
	<DOCNO>NCT00323310</DOCNO>
	<brief_summary>The purpose study assess safety enhance property magnetic resonance imaging ( MRI ) contrast agent MultiHance child age 2 17 year central nervous system ( CNS ) disorder .</brief_summary>
	<brief_title>Safety Efficacy MultiHance Pediatric Patients</brief_title>
	<detailed_description />
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Central Nervous System Diseases</mesh_term>
	<criteria>Between 2 17 year age Informed consent parent Assent patient require Known highly suspect disease CNS refer either cranial spinal MRI examination Contraindication MRI Undergoing MRI emergency situation Known allergy one ingredient MultiHance Sickle cell anemia moderate severe renal impairment Received another investigational compound within 30 day Pregnancy Lactating female Likely undergo invasive procedure within 72 hour receive MultiHance</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>disease central nervous system ( brain spine )</keyword>
</DOC>